Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9915491 | 0.89 | SMYD3 (0.45) | SMN1; SMN2LMNAMEN1KMT2APOLB | |
| SCHEMBL16748652 | 0.83 | MEN1 (0.42) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL15279079 | 0.81 | TLR7 (0.45) | LMNAMEN1KMT2ARAB9ATLR7 | |
| SCHEMBL9915519 | 0.78 | MEN1 (0.44) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL16747359 | 0.78 | MAPT (0.44) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL11362734 | 0.76 | KDM4E (0.59) | MAPTSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL14124965 | 0.73 | MEN1 (0.47) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL14124962 | 0.73 | NR1H4 (0.47) | SMN1; SMN2LMNAMEN1KMT2AHTT | |
| SCHEMBL11358221 | 0.73 | KDM4E (0.56) | MAPTHTTALDH1A1 | |
| SCHEMBL16748804 | 0.72 | NR1H4 (0.46) | SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | MAPT 3674/4885SMN1; SMN2 4574/4885LMNA 4489/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | MAPT 3674/4885SMN1; SMN2 4574/4885LMNA 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.